Restructurings, exit costs, and impairments under 8-K Items 2.05/2.06.
DHI GROUP, INC. announced a restructuring with charges of approximately $4.2 million affecting Dice brand (approximately 25%).
“$14.0 million to $16.0 million. The savings will begin to be realized immediately subsequent to the restructuring. The Company estimates that it will incur approximately $4.2 million in cash charges related to employee severance and benefits. Substantially all charges are expected to be recognized in the second quarter of 2025 while the related cash payments”
CYPHERPUNK TECHNOLOGIES INC. announced a restructuring with charges of approximately $3.2 million affecting the Company's research and development activities, including the Company's sirexatamab and FL-501 development programs (approximately 75% of the Company's current workforce).
“Due to current market conditions and the financial position of Leap Therapeutics, Inc. (the “Company”), the Company’s Board of Directors has approved a series of measures to conserve cash and reduce operating costs, including (i) the completion of the DeFianCe clinical trial and the wind-down of the Company’s research and development activities, including the Company’s sirexatamab and FL-501 development programs, and (ii) a reduction in force that will impact approximately 75% of the Company’s current workforce (the “Reduction In Force”) to be implemented in two phases (a) first, on or about June 30, 2025 that will impact the Company’s Chief Operating Officer, and (b) second, on or about July 31, 2025 that will impact the Chief Medical Officer of the Company. The Company estimates that it will incur approximately $3.2 million in costs primarily related to severance payments and related expenses in connection with the Reduction In Force.”
MAMMOTH ENERGY SERVICES, INC. announced a impairment with charges of ranging between $7.7 million and $9.2 million affecting hydraulic fracturing business.
“As a result, the Company expects to recognize impairment expense during the second quarter of 2025 ranging between $7.7 million and $9.2 million.”
JABIL INC announced a restructuring with charges of approximately $200 million.
“The Company expects the total amount of pre-tax restructuring and other related costs to be approximately $200 million, including the following estimated items: • $60 million to $70 million of employee severance and benefit costs; • $65 million to $70 million of asset write-off costs; and • $55 million to $65 million of contract termination costs and other related costs.”
PROTHENA CORP PUBLIC LTD CO announced a restructuring with charges of approximately $16 to $20 million (approximate 63% reduction in its workforce).
“periods will be extended, pursuant to the terms of the option award agreements under which those stock options were granted. The Company expects to recognize approximately $16 to $20 million in total for severance and related benefits for employees laid off under the reduction in workforce and non-cash share-based compensation expense related to the”
WESTLAKE CORP announced a restructuring with charges of approximately EUR 190 million affecting Pernis facility (approximately 230 employees).
“On June 17, 2025, the Company notified the affected employees at the Pernis facility of the Company's plan. The anticipated closure of the entire Pernis facility would take place after the conclusion of the consultations with local works councils and unions. In addition to the previous charges related to the July 2024 mothballing, the Company expects it would incur total pre-tax costs of approximately EUR 190 million related to the closure of the Pernis facility.”
VINEBROOK HOMES TRUST, INC. announced a impairment with charges of $5.7 million.
“on June 10, 2025, in connection with the Externalization described above, the Company estimates it will recognize $5.7 million in non-cash impairment of finite-lived intangible assets related to capitalized software development costs”
VINEBROOK HOMES TRUST, INC. announced a restructuring with charges of $2.8 million to $3.1 million (approximately 500 employees, representing 100% of our full-time employees).
“in force by the end of 2025. The Company estimates it will recognize aggregate pre-tax cash expenditures related to severance and one-time termination benefits ranging from $2.8 million to $3.1 million, the majority of which is expected to be paid in the fourth quarter of 2025. The implementation of the headcount reductions, including cash payments, is expected”
ADC Therapeutics SA announced a restructuring with charges of approximately $6 million to $7 million affecting U.K. research and development facility (approximately 30%).
“On June 11, 2025, the Board of Directors of the Company approved a strategic reprioritization and restructuring plan (the “Restructuring”) to focus resources on ZYNLONTA® (loncastuximab tesirine-lpyl) expansion opportunities and the advancement of its preclinical exatecan-based ADC targeting prostate-specific membrane antigen (PSMA). The Company will discontinue early development efforts for the remaining preclinical programs in solid tumors. In connection with the Restructuring, the Company plans to shut down its U.K. research and development facility and reduce its global workforce across functions by approximately 30%, which is expected to be substantially completed by September 30, 2025. The Company estimates that it will incur one-time pre-tax restructuring charges of approximately $6 million to $7 million for employee severance, benefits and related termination costs, the majority of which the Company expects to be recognized in the second quarter of 2025.”
RECURSION PHARMACEUTICALS, INC. announced a restructuring with charges of approximately $11 million (approximately 20%).
“into the fourth quarter of 2027. These changes are expected to result in a workforce reduction of approximately 20%. The Company estimates that it will incur approximately $11 million in charges in connection with the workforce reduction, consisting of severance payments, employee benefits, and related costs, substantially all of which the Company expects to”
NOVANTA INC announced a restructuring with charges of approximately $20 million to $25 million.
“strategies in areas anticipated to have a minimal long-term impact on the Company's overall business performance. The Company estimates that it will incur approximately $20 million to $25 million in pre-tax charges in connection with the 2025 Restructuring Plan, consisting of employee-related costs, third-party manufacturing moving costs, contract”
ZoomInfo Technologies Inc. announced a restructuring with charges of $4 million to $5 million (approximately 6%).
“The Plan includes a reduction of current employees by approximately 6% in the second quarter of 2025. The Company estimates the aggregate costs associated with the Plan to be approximately $4 million to $5 million, primarily consisting of severance payments, employee benefits, and related costs.”
LyondellBasell Industries N.V. announced a impairment affecting Olefins & Polyolefins-Europe, Asia, International (O&P-EAI) segment, including facilities at Carrington (UK), Tarragona (Spain), Münchsmünster (Germany), and Berre (France).
“All other long-lived assets of the Target Group have been fully impaired as of June 2025.”
LyondellBasell Industries N.V. announced a restructuring with charges of approximately $700 million to $900 million affecting Olefins & Polyolefins-Europe, Asia, International (O&P-EAI) segment, including facilities at Carrington (UK), Tarragona (Spain), Münchsmünster (Germany), and Berre (France).
“LYB expects to recognize a loss on sale estimated to be approximately $700 million to $900 million.”
Sunnova Energy International Inc. announced a restructuring (approximately 718 employees (approximately 55% of the Company's workforce)).
“On May 29, 2025, the Special Committee of the Board of Directors of the Company approved a reduction in force (the “Reduction in Force”), effective May 30, 2025, of approximately 718 employees (approximately 55% of the Company’s workforce)”
GOODYEAR TIRE & RUBBER CO /OH/ announced a restructuring with charges of between $100 million and $110 million affecting Europe, Middle East and Africa (“EMEA”) business unit (approximately 900 job reductions).
“On June 2, 2025, The Goodyear Tire & Rubber Company (the “Company”) approved a proposed plan to close our manufacturing facility in Kariega, South Africa in the Europe, Middle East and Africa (“EMEA”) business unit. The proposed plan includes approximately 900 job reductions, including associates and contracted positions, and is expected to be substantially complete by the end of 2025. The total charges associated with this action are expected to be between $100 million and $110 million, of which $45 million to $55 million are expected to be cash charges primarily for associate-related and other exit costs and the remaining costs are expected to be non-cash charges primarily for accelerated depreciation and other asset-related charges.”
Transocean Ltd. announced a impairment with charges of between $1.1 billion and $1.2 billion affecting GSF Development Driller I, Discoverer Luanda, Development Driller III, Discoverer Inspiration.
“the Company concluded that it expects its second quarter 2025 results to include an estimated non-cash charge ranging between $1.1 billion and $1.2 billion associated with the impairment of these rigs and related assets.”
Simulations Plus, Inc. announced a restructuring with charges of approximately $0.7 million (approximately 23 employees).
“The reduction in workforce will decrease overall headcount by approximately 23 employees, which represents approximately 10% of full-time employees as of the Effective Date. The Company estimates that it will incur approximately $0.7 million in charges in connection with the restructuring, consisting of severance payments, employee benefits, and related costs”
NORTECH SYSTEMS INC announced a restructuring with charges of approximately $1.0 million to $1.1 million affecting Blue Earth, Minnesota manufacturing plant.
“On May 16, 2024, the Registrant issued a press release, attached hereto as Exhibit 99.1, announcing that the Registrant will close its manufacturing plant located in Blue Earth, Minnesota and relocate the production of products made in that facility to its facility in Bemidji, Minnesota. The registrant further announced that it expects this closure to result in out-of-pocket expenses for employee severance and other plant closure expenses of approximately $1.0 million to $1.1 million, including asset write-offs of about $0.4 million.”
Erasca, Inc. announced a restructuring with charges of approximately $2.2 million affecting drug discovery functions or on the deprioritized programs (by approximately 18%).
“by approximately 18%, primarily affecting employees working in drug discovery functions or on the deprioritized programs. The Company anticipates recognizing approximately $2.2 million in total charges in the second quarter of 2024 in connection with the reduction in force. These charges will consist primarily of one-time cash charges for termination benefits.”
Under Armour, Inc. announced a restructuring with charges of approximately $70 million to $90 million.
“On May 15, 2024, the Company’s Board of Directors approved a restructuring plan designed to rebalance the Company’s cost base to further improve profitability and cash flow generation. In connection with the restructuring plan, the Company expects to incur total estimated pre-tax restructuring and related charges of approximately $70 million to $90 million during fiscal year 2025”
Tenaya Therapeutics, Inc. announced a restructuring with charges of $1.3 million to $1.5 million (approximately 22% of the workforce).
“Employees impacted by the Workforce Reduction were notified on May 13, 2024, and represent approximately 22% of the workforce. In connection with the Workforce Reduction, Tenaya estimates that it will incur approximately $1.3 million to $1.5 million, of aggregate charges, primarily related to employee cash severance and continuing health benefits, which costs are expected to be substantially recognized during the second quarter of 2024.”
Bolt Biotherapeutics, Inc. announced a restructuring with charges of $3.0 million to $4.0 million affecting Bolt Biotherapeutics (approximately 50 employees, or approximately 50% of the Company's workforce).
“On May 14, 2024, the Company announced a strategic pipeline prioritization and restructuring plan pursuant to which it will discontinue developing trastuzumab imbotolimod, formerly known as BDC-1001, in order to focus on the Company’s next generation ISAC platform including new clinical candidate, BDC-4182, targeting Claudin 18.2, and Phase 1 asset, BDC-3042, a Dectin-2 agonist antibody, and reduce overall operating expenses to preserve cash. The restructuring plan includes a reduction of the Company’s current workforce by approximately 50 employees, or approximately 50% of the Company’s workforce. The Company estimates that it will incur aggregate pre-tax charges between approximately $3.0 million to $4.0 million in connection with the reduction-in-force, primarily consisting of severance payments, employee benefits, and related costs.”
BIOMARIN PHARMACEUTICAL INC announced a restructuring with charges of approximately $15 - $20 million affecting research and development programs (approximately 170 employees).
“In connection with the discontinuation of certain research and development programs, on May 9, 2024, the Company committed to a plan to reduce its global workforce by approximately 170 employees. The Company estimates that it will incur aggregate pre-tax charges of approximately $15 - $20 million during the second quarter of 2024, representing one-time cash expenditures for severance and other employee termination benefits.”
Vintage Wine Estates, Inc. announced a restructuring with charges of $0.6 million (approximately 10% of the workforce).
“On May 8, 2024, as a result of the Company's financial condition, the Company's Board of Directors approved a reduction in force affecting approximately 10% of the workforce. The Company expects the reduction in force to be substantially complete by the end of the fourth quarter of fiscal 2024. Cash expenditures for the reduction in force are estimated to be $0.6 million, substantially all of which are related to employee severance and benefits costs.”
Nxu, Inc. announced a restructuring with charges of approximately $837,000 affecting product, engineering, manufacturing and general and administrative functions.
“On May 8, 2024, Nxu, Inc (the “Company”) committed to reducing its headcount under a plan of termination as part of the Company’s efforts to reduce operating expenses and conserve cash resources in light of its intention to evaluate strategic alternatives. The plan of termination primarily impacts employees across the Company’s product, engineering, manufacturing and general and administrative functions. The Company expects the headcount reduction to be complete by May 10, 2024. The Company expects to record approximately $837,000 of charges in the second quarter of 2024 related to employee severance costs.”
MEDICAL PROPERTIES TRUST INC announced a impairment with charges of approximately $470 million of additional impairment charges affecting investments in Steward, including 9.9% equity interest and $362 million loan due from affiliates of Steward.
“the Company has concluded the investments in Steward have been further materially impaired and has recorded approximately $470 million of additional impairment charges in the quarter ended March 31, 2024 that fully reserves for the remaining value of our 9.9% equity interest in Steward and the $362 million loan due from affiliates of Steward, along with an accrual for property taxes and obligations not paid by Steward under its master leases.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.